AKT1 and small cell lung carcinoma: Additionally, MYC-driven SCLC has shown heightened sensitivity to Aurora kinase inhibitors—serine/threonine protein kinases that, when overexpressed, promote tumor cell proliferation and survival in SCLC (72, 73).